Detail akcie Santhera Pharm H Rg online

Business Summary: Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Santhera Pharmaceuticals Holding AG revenues increased from SF3.9M to SF14.1M. Net loss decreased 35% to SF15.3M. Revenues reflect Europe segment increase from SF2M to SF6.6M, Asia segment increase from SF1.9M to SF5.4M. Lower net loss reflects Development and commercialization of products for the treatm segment loss decrease of 13% to SF17.7M.